LivaNova PLC
LIVNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeLivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The $4.50B market capitalization puts LIVN squarely in mid-cap range for its industry. The company operates in two segments, Cardiopulmonary and Neuromodulation.
Market Cap
$4.50B
Beta
0.87
P/E (TTM)
24.17
P/E (Fwd)
17.52
EPS (TTM)
$3.39
EPS (Fwd)
$4.68
ROE
15.4%
ROA
5.0%
Cash
$516.6M
Total Debt
$351.9M
Free CF
$59.9M
52W Change
39.5%
Annual Financials
Cash vs Debt
Where LIVN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, LIVN finished 11.49% above its 150-day moving average ($71.90) and 15.54% above its 200-day moving average ($69.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LIVN overbought or oversold?
At the September 2, 2026 close, LIVN's RSI(14) was 47.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $516.6M in cash and $351.9M in debt, LIVN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $59.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 15.4%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.02B (2022) to $1.39B (2025), reflecting a 36% increase over the period.
Investors considering LivaNova PLC should weigh the typical risks associated with LIVN's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LIVN.